Oncolytic viruses & their specific targeting to tumour cells

Indian Journal of Medical Research

Volumn 136, Issue 4, 2012, Pages 571-584

  Singh, Prafull K ^a   Doley, Juwar ^a   Ravi Kumar, G ^a   Sahoo, A P ^a   Tiwari, Ashok K ^a  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

Author keywords

Apoptosis; Oncolytic viruses; Tumour targeting; Viral oncotherapy

Indexed keywords

ONCOLYTIC VIRUS; SURVIVIN;

ADENOVIRUS; APOPTOSIS; CANCER THERAPY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; GYROVIRUS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HERPES SIMPLEX VIRUS; HUMAN; MELANOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PARVOVIRUS; PATHOGENESIS; REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT; VESICULAR STOMATITIS VIRUS; VIRION; VIROTHERAPY;

APOPTOSIS; DRUG DELIVERY SYSTEMS; GENETIC ENGINEERING; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES;

EID: 84869078019     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (132)

1. Fvsky B, Orrenius S. Carcinogenesis and apoptosis: Paradigms and paradoxes. Carcinogenesis 2006; 27: 1939-45.
2. Abell JC, Litchy Stojdl D. Getting oncolytic virus therapies off the ground. Cancer cell 2003; 4: 7-11.
3. Dorer DE, Nettelbeck DM. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 2009; 61: 554-71.
4. Ries SJ, brandts CH. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov Today 2004; 9: 759-68.
5. Roulston A, Marcellus RC, branton PE. Viruses and apoptosis. Annu Rev Microbiol 1999; 53: 1-60.
6. Hay S, Kannourakis G. A time to kill: viral manipulation of the cell death program. J Gen Virol 2002; 83: 1547-64.
7. Johnson DC, Huber MT. Directed egress of animal viruses promotes cell to cell spread. J Virol 2002; 76: 1-8.
8. Hofmann J, Pletz WR, Liebert UG. Rubella virus-induced cytopathic effect in vitro is caused by apoptosis. J Gen Virol 1999; 80: 1657-64.
9. Danen-van Oorschot AA, van Der Eb AJ, Noteborn MH. The chicken anemia virus-derived protein apoptin requires activation of caspases for induction of apoptosis human tumor cells. J Virol 2000; 74: 7072-8.
10. Danen van Oorschot AA, Fischer DF, Grimbergen JM, Klein B, Zhuang SM, Falkenburg JHF et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA 1997; 94: 5843-7.
11. Chang CJ, Shih WL, Yu FL, Liao MH, Liu HJ. Apoptosis induced by bovine ephemeral fever virus. J Virol Methods 2004; 122: 165-70.
12. Li XD, Kukkonen S, Vapalahti O, Plyusnin A, Lankinen H, Vaheri A. Tula hantavirus infection of Vero E6 cells induces apoptosis involving caspase 8 activation. J Gen Virol 2004; 85: 3261-7.
13. Heise C, Hermiston T, Johnson L, brooks G, Sampson-Johannes A, Williams A. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nature Med 2000; 6: 1134-9.
14. Raus RC, Teodoro JG, Wu T, brough DE, Ketner G, Shore GC, et al. Adenovirus type 5 early region 4 is responsible for EIA-induced p53-independent apoptosis. J Virol 1996; 70: 6207-15.
15. Ravindra PV. Elucidation of apoptotic pathways induced by Newcastle disease virus in cultured cells and assessment of its Oncolytic potential in experimentally induced tumor. Ph.D. thesis. Indian Veterinary Research Institute (Deemed University) Izatnagar, Uttar Pradesh; 2008.
16. Han J, Sabbatini P, Perez D, Rao L, Modha D, White E. The E1B19k protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting bax protein. Genes Dev 1996; 10: 461-77.
17. Farrow SN, White JHM, Martinou I, Raven T, Pun KT, Grinham CJ, et al. Cloning of a bcl-2 homolog by interaction with adenovirus E1B19k. Nature 1995; 374: 731-3.
18. Krajcsi P, Dimitrov T, Hermiston TW, Tollefson AE, Ranheim TS, Van de Pol SB, et al. The adenovirus E3-14±7k protein and the E3-10.4k,14.5k complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid. J Virol 1996; 70: 4904-13.
19. Chen P, Tian J, Kovesdi I, bruder JT. Interaction of the adenovirus 14.7 kDa protein with FLICE inhibits Fas ligand-induced apoptosis. J Biol Chem 1998; 273: 5815-20.
20. Afonso CL, Neilan JG, Kutish GF, Rock DL. An African swine fever virus bcl-2 homologue, 5-HL, suppresses apoptotic cell death. J Virol 1996; 70: 4858-63.
21. Valle GF, banks L. The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J Gen Virol 1995; 76 1239-45.
22. Clem RJ, Hardwick JM, Miller LK. Anti-apoptotic genes of baculoviruses. Cell Death Differ 1996; 3: 9-16.
23. Bertin J, Mendrysa SM, LaCount DJ, Gaur S, Krebs JF, Armstrong RC, et al. Apoptotic suppression by baculovirus P35 involves cleavage by and inhibition of a virus-induced CED-3/ICE-like protease. J Virol 1996; 70: 6251-9.
24. Talley AK, Dewhurst S, Perry SW, Dollard SC, Gummuluru S, Fine SM, et al. Tumor necrosis factor alpha-induced apoptosis in human neuronal cells: protection by the antioxidant N-acetylcysteine and the genes bcl-2 and crmA. Mol Cell Biol 1995; 15: 2359-66.
25. Okan I, Wang YS, Chen F, Hu LF, Imreh S, Klein G, et al. The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 1995; 11: 1027-31.
26. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A. Epstein-barr virus-coded bHRF1 protein, a viral homolog of bcl-2, protects human b-cells from programmed cell-death. Proc Natl Acad Sci USA 1993; 90: 8479-83.
27. Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Sturzbecher HW, et al. Abrogation of p53-induced apoptosis by the hepatitis b virus x gene. Cancer Res 1995; 55: 6012-6.
28. Ray RB, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology 1996; 226: 176-82.
29. Zhu H, Shen YQ, Shenk T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J Virol 1995; 69: 7960-70.
30. Nava VE, Cheng EHY, Veliuona M, Zou SF, Clem RJ, Mayer ML, et al. Herpesvirus saimiri encodes a functional homolog of the human bcl-2 oncogene. J Virol 1997; 71: 4118-22.
31. Chou J, Roizman b. The gamma-1 34.5 gene of herpes simplex virus-1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell-death in neuronal cells. Proc Natl Acad Sci USA 1992; 89 3266-70.
32. Thome M, Schneider P, Hofmann K, Fickenscher H, Meini E, Neipel F, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997; 386: 517-21.
33. Cheng EHY, Nicholas J, bellows DS, Hayward GS, Guo HG, Reitz MS. A bcl-2 homolog encoded by Kaposi sarcoma-associated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with bax or bak. Proc Natl Acad Sci USA 1997; 94: 690-4.
34. Scheffner M, Werness bA, Huibregtse J M, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus type-16 and type-18 promotes the degradation of p53. Cell 1990; 63: 1129-36.
35. Pan HC, Griep AE. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes Devel 1995; 9: 2157-69.
36. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 1997; 16: 504-14.
37. Su J, Wang G, barrett JW, Irvine TS, Gao X, McFadden G. Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of bax at the mitochondria. J Virol 2006; 80: 1140-51.
38. Finkel TH, Tudorwilliams G, banda NK, Cotton MF, Curiel T, Monks C, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-infected and SIV-infected lymph nodes. Nature Med 1995; 1: 129-34.
39. Sastry KJ, Marin MC, Nehete PN, McConnell K, Elnaggar AK, McDonnell TJ. Expression of human immunodeficiency virus type-1 Tat results in down-regulation of bcl-2 and induction of apoptosis in hematopoietic cells. Oncogene 1996; 13: 487-93.
40. McCarthy SA, Symonds HS. Van Dyke T. Regulation of apoptosis in transgenic mice by simian-virus-40 T-antigen-mediated inactivation of p53. Proc Natl Acad Sci USA 1994; 91: 3979-83.
41. Dobbelstein M, Shenk T. Protection against apoptosis by the vaccinia virus SPI-2 (b13R) gene product. J Virol 1996; 70: 6479-85.
42. Morey AL, Ferguson DJP, Fleming KA. Ultrastructural features of fetal erythroid precursors infected with parvovirus-B19 in vitro evidence of cell-death by apoptosis. J Pathol 1993; 169: 213-20.
43. P, Diazguerra M, Prieto C, Esteban M, Castro, JM, Nieto A, et al. Open reading frame-5 of porcine reproductive and respiratory syndrome virus as a cause of virus-induced apoptosis. J Virol 1996; 70: 2876-82.
44. Ravindra PV, Tiwari AK, Ratta b, bais MV, Chaturvedi U, Palia SK, et al. Time course of Newcastle disease virus-induced apoptotic pathways. Virus Res 2009; 144: 350-4.
45. Quintieri L, Fantin M, Vizler C. Identification of molecular determinants of tumor sensitivity and resistance to anticancer drugs. Adv Exp Med Biol 2007; 593: 95-104.
46. Daniel S. Transcription-independent p53 apoptosis: an alternative route to death. Trends Cell Biol 2009; 20: 14-24.
47. Rodriguez-Nieto S, Zhivotovsky Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des 2006; 12: 4411-25.
48. Walensky LD. bCL-2 in the crosshairs: tipping the balance of life and death. Cell Death Differ 2006; 13: 1339-50.
49. Muthumani K, Choo AY, Hwang DS, Ugen KE, Weiner DB. HIV-1 Vpr: enhancing sensitivity of tumors to apoptosis. Curr Drug Deliv 2004; 1: 335-44.
50. Hermiston TW, Kuhn I. Armed therapeutic viruses: strategies and challenges to arming oncolytic viruses with therapeutic genes, Cancer Gene Ther 2002; 9: 1022-35.
51. Harrison SC. Principles of virus structure. In: Knipe DM, Howley PM, editors. Fields virology. Lippincott Williams and Wilkins; 2001. p. 53-85.
52. Russell SJ, Peng KW. Viruses as anticancer drugs. Trends Pharmacol Sci 2007; 28: 326-33.
53. Pack GT. Note on the experimental use of rabies vaccine for melanomatosis, AMA Arch Derm Syphilol 1950; 62: 694-5.
54. Ring CJA. Cytolitic viruses as potential anticancer agents. J Gen Virology 2002; 7: S293.
55. Vähä-Koskela M. J, Heikkilä JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254: 178-216.
56. Guo ZS, Thorne SH, bartlett DL. Oncolytic virotherapy: Molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785: 217-31.
57. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007; 15: 651-9.
58. Russell SJ. Replicating vectors for cancer therapy: a question of strategy. Semin Cancer Biol 1994; 5: 437-43.
59. Novella IS, Gilbertson DL, borrego b, Domingo E, Holland JJ. Adaptability costs in immune escape variants of vesicular stomatitis virus. Virus Res 2005; 107: 27-34.
60. Bouchet BP, de Fromentel CC, Puisieux A, Galmarin CM. p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 2006; 58: 190-207.
61. Dobbelstein M. Replicating adenoviruses in cancer therapy. Curr Top Microbiol Immunol 2004; 273: 291-334.
62. Ko D, Lynda Hawkins L, Yu DC. Development of transcriptionally regulated oncolytic adenoviruses. Oncogene 2005; 24: 7763-74.
63. Zaho T, Rao XM, Xie X, Li L, Thompson TC, McMasters KM, et al. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 2003; 63: 3073-8.
64. Los M, Panigrahi S, Rashedi I, Mandal S, Stetefeld J, Essmann F, et al. Apoptin, a tumor-selective killer. Biochim Biophys Acta 2009; 1793: 1335-42.
65. Stojdl DF, Lichty bD, benjamin R, tenOever bR, Paterson JM, Power AT, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003; 4: 263-75.
66. Mansour M, Palese P, Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol 2011; 85: 6015-23.
67. Lazar I, Yaacov b, Shiloach T, Eliahoo E, Kadouri L, Lotem M, et al. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J Virol 2010; 84: 639-46.
68. Sarinella F, Calistri A, Sette P, Palu G, Parolin C. Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Ther 2006; 13: 1080-7.
69. Palmer D H, Lawrence S Young, Vivien Mautner. Cancer gene-therapy: clinical trials. Trends Biotechnol 2006; 24: 76-82.
70. Sapuntzakis MS, Duncan C, Sharifi R, Ghosh L, van Breemen R, et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 2001; 93: 1872-9.
71. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 2003; 22: 2065-72.
72. Dalba C, Klatzmann D, Logg CR, Kasahara N. Beyond oncolytic virotherapy: replication-competent retrovirus vectors for selective and stable transduction of tumors. Curr Gene Ther 2005; 5: 655-67.
73. Springfeld C, von Messling V, Frenzke M, Ungerechts G, Buchholz CJ, Cattaneo R. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metallo proteinases. Cancer Res 2006; 66: 7694-700.
74. Au GG, Lindberg AM, barry RD, Shafren DR. Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21. Int J Oncol 2005; 26: 1471-6.
75. Shafren DR, Sylvester D, Johansson ES, Campbell IG, Barry RD. Oncolysis of human ovarian cancers by echovirus type 1. Int. J. Cancer 2005; 115: 320-8.
76. Ochiai H, Campbell SA, Archer GE, Chewning TA, Dragunsky E, Ivanov M, et al. Targeted therapy for glioblastoma multiforme neoplastic meningitis with intrathecal delivery of an oncolytic recombinant poliovirus. Clin. Cancer Res 2006; 12: 1349-54.
77. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006; 80: 5145-55.
78. Ido A, Uto H, Moriuchi A, Nagata K, Onaga Y, Onaga M, Hori T, et al. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a humanα-fetoprotein promoter. Cancer Res 2001; 61: 3016-21.
79. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006; 5: 755-66.
80. Power AT, Wang J, Falls TJ, Paterson JM, Parato KA, Lichty et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007; 15: 123-30.
81. Coukos G, Makrigiannakis A, Kang EH, Caparelli D, Benjamin I, Kaiser LR, et al. Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res 1999; 5: 1523-37.
82. Raykov Z, balboni G, Aprahamian M, Rommelaere J. Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer 2004; 109: 742-9.
83. Ganly I, Kirn D, Eckhardt G, Rodriguez GI, Soutar DS, Otto R, et al. A phase I study of Onyx-015, an E1Battenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000; 6: 798-806.
84. Meier O, Greber UF. Adenovirus endocytosis, J Gene Med 2003; 5: 451-62.
85. White E, Gooding LR. Regulation of apoptosis by human adenoviruses. Curr Commun Cell Mol Biol 1994; 8: 111-4.
86. Jiang H, Olson MV, Medrano DR, Lee OH, Xu J, Piao Y, et al. A novel CRM1-dependent nuclear export signal in adenoviral E1A protein regulated by phosphorylation. Faseb J 2006; 20: 2603-5.
87. Dbarker DD, berk AJ. Adenovirus proteins from both E1b reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107-12.
88. Nemunaitis J, Khuri F, Ganly I, Arseneau J, Posner M, Vokes E, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neckcancer. J Clin Oncol 2001; 19: 289-98.
89. Shea CCO, Soria C, bagus b, McCormick F, Heat shock phenocopies E1b-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005; 8: 61-74.
90. Fueyo J, Manzano G, Alemany R, Lee PS, McDonnell TJ, Mitlianga P, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
91. Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J. Oncolytic adenoviruses are emerging as a promising alternative therapy for glioma patients and are currently being tested in clinic. Curr Gene Ther 2009; 9: 422-7.
92. Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR, McNeish IA. Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 2008; 27: 3081-90.
93. Noteborn MH, de Boer GF, van Roozelaar DJ, Karreman C, Kranenburg O, Vos JG, et al. Characterization of cloned chicken anemia virus DNA that contains all elements for the infectious replication cycle. J Virol 1991; 65: 3131-9.
94. Todd D. Circoviruses: immunosuppressive threats to avian species: a review. Avian Pathol 2000; 29: 373-94.
95. Noteborn MH. Chicken anemia virus induced apoptosis: underlying molecular mechanisms. Vet Microbiol 2004; 98: 89-94.
96. Gboukamp P, Petrussevska RT, breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol 1988; 106: 761-71.
97. Danen-van Oorschot AA, Voskamp P, Seelen MC, van Miltenburg MH, bolk MW, Tait SW, et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist apoptin and exerts tumor-preferential cell killing. Cell Death Differ 2004; 11: 564-73.
98. Maddika S, booy EP, Johar D, Gibson Sb, Ghavami S, Los M. Cancer specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J Cell Sci 2005; 118: 4485-93.
99. Zhuang SM, Shvarts A, van Ormondt H, Jochemsen AG, van der Eb AJ, Noteborn MH. Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res 1995; 55: 486-9.
100. Peng DJ, Sun J, Wang JYZ, Tian J, Zhang, YH, Noteborn MH, et al. Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor. Cancer Gene Ther 2007; 14: 66-73.
101. Olijslagers SJ, Zhang YH, backendorf C, Noteborn MH. Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin Pharmacol Toxicol 2007; 100: 127-31.
102. Lian H, Jin N, Li X, Mi Z, Zhang J, Sun L, et al. Induction of an effective anti-tumor immune response and tumor regression by combined administration of IL-18 and Apoptin. Cancer Immunol Immunother 2007; 56: 181-92.
103. Natesan S, Kataria JM, Dhama K, bhardwaj N, Sylvester A. Anti-neoplastic effect of chicken anemia virus VP3 protein (apoptin) in Rous sarcoma virus-induced tumours in chicken, J Gen Virol 2006; 87: 2933-40.
104. Singh PK. Elucidation of molecular mechanism of apoptosis involved in apoptin induced oncolysis in tumor cell line. M.V. Sc thesis. Indian Veterinary Research Institute (Deemed University) Izatnagar, Uttar Pradesh; 2010.
105. Bauder B, Suchy A, Gabler C, Weissenbock H. Apoptosis in feline pauleukapenia and canine parvovirus enteritis. J Vet Med 2000; 47: 775-84.
106. Ozawa K, Ayub J, Kajigaya S, Shimada T, Young N. The gene encoding the nonstructural protein of b19 (human) parvovirus may be lethal in transfected cells. J Virol 1988; 62: 2884-9.
107. Rayet B, Lopez-Guerrero JA, Rommelaere J, Dinsart C. Induction of programmed cell death by parvovirus H-1 in U937 cells: connection with the tumor necrosis factor alpha-pathway. J Virol 1998; 72: 8893-903.
108. Sol N, Junter JL, Vassias I, Freyssinier JM, Thomas A, Prigent AF, et al. Possible interactions between the NS-1 protein and tumor necrosis factor alpha pathways in erythroid cell apoptosis induced by human parvovirus B19. J Virol 1999; 73: 8762-70.
109. Anouja F, Wattiez R, Mousset S, Caillet-Fauquet P. The cytotoxicity of the parvovirus minute virus of mice-structural protein NS1 is related to changes in the synthesis in the synthesis and phosphorylation of cell proteins. J Virol 1997; 71: 4641-78.
110. Telerman A, Tuynder M, Dupressoir T, Robaye b, Sigaux F, Shaulian E, et al. A model for tumor suppression using H-1 parvovirus. Proc Natl Acad Sci USA 1993; 90: 8702-6.
111. Zahari R, Svetlana G, Angel G, Ginette Ute K, Marc A, et al. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep 2007; 17: 1493-9.
112. Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, et al. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation and cross-presentation by dendritic cells. Hum Gene Ther 2005; 16: 996-1005.
113. Toolan HW, Saunders EL, Southam CM, Moore AE, Levin AG. H-1 virus viremia in the human. Proc Soc Exp Biol Med 1965; 119: 711-5.
114. Le Cesne A, Dupressoir T, Jamin N, Spielmann M, Le Chevalier T, Sancho-Garnier H, et al. Intra-lesional administration of live virus, parvovirus H-1, in cancer patients: a feasibility study. Proc Am Soc Clin Oncol 1993; 12: 297.
115. Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010, 21: 185-95.
116. Post DE, Fulci G, Chiocca EA, van Meir EG. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004; 4: 41-51.
117. Montgomery RI, Warner MS, Lum bJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family. Cell 1996; 87: 427-36.
118. Norman KL, Farassati F, Lee PW. Oncolytic viruses and cancer therapy. Cytokine Growth Factor Rev 2001; 12: 271-82.
119. Homa FL, brown JC. Capsid assembly and DNA packaging in herpes simplex virus. Rev Med Virol 1997; 7: 107-22.
120. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, brennan D, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;: 859-66.
121. SS, Nakamura H, Carroll NM, Bode BP, Chiocca EA, Tanabe KK. An oncolytic herpes simplex virus type selectively destroys diffuse liver metastases from colon carcinoma. FASEB J 2000; 14: 301-11.
122. Cassady KA, Parker JN. Herpesvirus vectors for therapy of brain tumors. Open Virol J 2010; 4: 103-8.
123. Filippakis H, Spandidos DA, Sourvinos G. Herpesviruses: Hijacking the Ras signaling pathway. Biochim Biophys Acta 2010; 1803: 777-85.
124. Krishnamurthy S, Samal SK. Nucleotide sequence of trailer nucleocapsid protein gene and intergenic region of Newcastle disease virus strain beaudette, C and completion of the entire genome sequence. J Gen Virol 1998; 79: 2419-24.
125. Park MS, Garcia-Sastre A, Cos JF, basler CF, Palese P. Newcastle disease virus V protein is a determinant of host range restriction. J Virol 2003; 77: 9522-32.
126. Lam KM. Growth of Newcastle disease virus in chicken macrophages. J Comp Pathol 1996; 115: 253-63.
127. Ravindra PV, Tiwari AK, Ratta Chaturvedi U, Palia SK, Chauhan RS Newcastle disease virus-induced cytopathic effect in infected cells is caused by apoptosis. Virus Res 2009; 141: 13-20.
128. Kommers GD, King DJ, Seal bS, brown CC. Pathogenesis of chicken passaged Newcastle disease viruses isolated from chickens and wild and exotic birds. Avian Dis 2003; 47: 319-29.
129. Ravindra PV, Tiwari AK, Sharma b, Rajawat YS, Ratta Palia S, et al. HN protein of Newcastle disease virus causes apoptosis in chicken embryo fibroblast cells. Arch Virol 2008; 153: 749-54.
130. Ravindra PV, Tiwari AK, Ratta Chaturvedi U, Palia SK, Subudhi PK, et al. Induction of apoptosis in Vero cells by Newcastle disease virus requires viral replication, de-novo protein synthesis and caspase activation. Virus Res 2008; 133 285-90.
131. Ravindra PV, Tiwari AK, Sharma b, Chauhan RS. Newcastle disease virus as an oncolytic agent. Indian J Med Res 2009; 130: 507-13.
132. Lorence RM, Pecora AL, Major PP, Hotte SJ, Laurie SA, Roberts MS, et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 2003; 5: 618-24.